PATENT FORAMEN OVALE
I. Pathophysiology
- The foramen ovale runs between the left and right atria and normally
closes soon after birth
- In 30% of humans it stays patent throughout life (mean diameter 4.9mm in
one study), providing a potential shunt between the atria
- Found more often in pts with idiopathic ischemic cerebrovascular accident
than in control subjects (Circ. 105:2580, 2002--JW). However, a causal relationship is unclear
and PFO may not be a sig. predictor of recurrence of idiopathic CVA.
- However, in a prospective study of
601 pts with ischemic CVA (mean age 59yo), all of whom underwent
transesophageal echocardiography, risk of recurrent CVA over 2y f/u were
not more common in those with patent foramen ovale or
atrial septal aneurysm on TEE (J. Am. Coll. Cardiol. 42:1077, 2003--JW)
- Also, in a case-control study
comparing pts with cryptogenic vs. non-cryptogenic CVA and controls
without history of cerebral ischemia (all undergoing transesophageal
echocardiography), after adjustment for potential confounders, the
prevalence of patent foramen ovale was not sig. higher in pts with
cryptogenic CVA ( (Mayo Clin. Proc. 81:602, 2006--JW)
- In a meta-analysis of four
controlled observational studies involving 1,081 pts with prior
cryptogenic CVA or TIA, over mean 31-42 f/u, there was no sig. diff.
among pts with or without PFOs in risk of recurrent CVA or TIA. (Neurol.
73:89, 2009-JW)
- Frequently associated with atrial septal aneurysm, itself associatedd with risk
of CVA
II. Diagnosis
- Transesophageal echocardiography with "bubble study" (injection
of microbubble contrast agents into systemic vein) is more sensitive than
standard transthoracic echo
- Sensitivity increased with Valsalva and coughing during echo
III. Treatment
- Impact of PFO closure on risk of CVA
- 308 pts with idiopathic CVA and PFO who underwent either medical tx of
PFO closure; over 4y f/u, the PFO recipients had no sig. diff in
incidence of (death, CVA, or TIA), though they had larger mean
right-to-left shunt and higher prevlance of having had > 1 CVA than
the medical-treatment group (J. Am. Coll. Cardiol. 44:750, 2004--abst)